Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00540696
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
Phase 1
Completed
- Conditions
- AnemiaSolid Tumors
- Interventions
- Drug: PlaceboDrug: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 405
- Registration Number
- NCT00540384
A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: AMG 655 placebo
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 172
- Registration Number
- NCT00534027
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
Phase 3
Terminated
- Conditions
- AnemiaCardiovascular DiseaseCongestive Heart FailureHeart FailureVentricular Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT00534456
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 164
- Registration Number
- NCT00530816
- Locations
- 🇺🇸
Therapeutic Research Institute of Orange County, Laguna Hills, California, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1
Completed
- Conditions
- Renal CancerLymphomaNon-small Cell Lung CancerSolid TumorsOvarian CancerSmall Cell Lung CancerMultiple Myeloma
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 184
- Registration Number
- NCT00531284
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
Phase 2
Completed
- Conditions
- End Stage Renal DiseaseHyperphosphatemicKidney DiseaseChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 167
- Registration Number
- NCT00530114
Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 320
- Registration Number
- NCT00527267
12-month Study of AMG 073 in Renal Osteodystrophy
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00527085
NESP Pediatric Study
Phase 3
Completed
- Conditions
- Pre-dialysisEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT00527137
© Copyright 2025. All Rights Reserved by MedPath